choosing second-line therapy for patients with urothelial carcinoma
Published 7 years ago • 82 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
3:04
mrcc: factors for choosing second-line therapy
-
1:04
treatment considerations for patients with metastatic urothelial carcinoma
-
1:54
targeted therapy effective for patients with advanced bladder cancer and specific gene mutations
-
1:56
analyzing frontline options for patients with bladder cancer
-
3:37
optimal treatment strategies for patients with metastatic urothelial carcinoma
-
2:16
second-line therapy for metastatic renal cell cancer
-
1:36
evaluating second-line treatment options in bladder cancer
-
8:24
case 2: combination therapy for cis-ineligible bladder cancer
-
3:35
second-line therapy for metastatic colon cancer
-
14:16
new emerging treatment options and targeted therapies for bladder cancer
-
8:08
second-line therapy for metastatic colorectal cancer
-
19:31
second line bladder cancer therapies when first line treatments fail
-
1:23
recent advances in the use of targeted therapies for metastatic urothelial carcinoma
-
1:03:24
bladder cancer: understanding immune-, targeted-, and antibody-based models for patient care
-
1:41
dr. petrylak on immunotherapy for second-line treatment in bladder cancer
-
6:38
case 2: exciting new treatment for cis-ineligible bladder cancer
-
1:34
dr. singh on patient selection for immunotherapy in bladder cancer
-
43:17
case-based panel discussion: muscle-invasive bladder cancer
-
2:14
how does targeted therapy treat bladder cancer?